Hepatocellular Carcinoma
Conditions
Keywords
Hepatocellular carcinoma, HCC, Hepatoma, primary liver tumours
Brief summary
EASL and mRECIST criteria differ from each other in terms of the number of target lesions (all versus \< = 2) and calculation method (bidimensional versus unidimensional). Therefore, the investigators aimed to retrospectively analyze and compare the clinical outcomes among patients with hepatocellular carcinoma who were treated with different modalities of therapy according to the BCLC classification, and detect the possible predictors of post-treatment outcomes.
Detailed description
Background: EASL and mRECIST criteria differ from each other in terms of the number of target lesions (all versus \< = 2) and calculation method (bidimensional versus unidimensional). Therefore, the investigators aimed to retrospectively analyze and compare the clinical outcomes among patients with hepatocellular carcinoma (HCC) who were treated with different modalities of therapy according to the BCLC classification, and detect the possible predictors of post-treatment outcomes. Methods: This work was conducted at the departments of tropical medicine and gastroenterology, internal medicine, and general surgery. This study included patients that matched our eligibility criteria for a period of five years started from June 2015 to May 2020. The study purpose was to retrospectively analyze the clinical outcomes among patients with HCC who were treated with different modalities of therapy according to the BCLC classification, and detect the possible predictors of post-treatment favorable outcomes. The data of the patients were extracted and retrospectively reviewed from the patients' records and the databases of both hospitals (SUH and SOI). During the period of recruitment, 407 patients diagnosed with HCC admitted to our departments and followed-up attending outpatient clinics, Sohag University Hospitals, over a 5 years period.
Interventions
DEVICERadiofrequency ablation
Radiofrequency ablation of the tumour
DRUGTrance-arterial chemoembolization
Trance-arterial chemotherapy
PROCEDURELiver resection
non-anatomical or anatomical liver resection
COMBINATION_PRODUCTCombined radiofrequency ablation + percutaneous ethanol injection
combined therapy
Percutaneous ethanol injection of HCC
DRUGSystemic chemotherapy
Systemic chemotherapy
DRUGSorafenib
Sorafenib
DIETARY_SUPPLEMENTViscum
Viscum for HCC
Symptomatic treatment
Sponsors
Sohag University
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Adult patients * with hepatocellular carcinoma
Exclusion criteria
* severely-ill patients * With other system comorbidities, * presence of extrahepatic metastasis, * patients who dropped from the follow-up list after treatment.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| CURE (Number of patients cured completely from the disease) | one-year | the HCC is treated (disappearance of all lesions) |
| STABLE Disease (Number of patients with neither progression nor cure from the disease) | one-year | NONE of the other outcomes' criteria |
| PROGRESSIVE((Number of patients with progression of the disease) (measured by follow-up CT scans, increase in size, appearance of new intratumoral lesions, or appearance of new lesions | one-year | increase in size - appearance of new intratumoral lesions - new lesions |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| DEATH (Number of patients died from the disease) | one-year | Mortality rate |
Outcome results
None listed